nodes	percent_of_prediction	percent_of_DWPC	metapath
Nabumetone—osteoarthritis—Prednisone—prostate cancer	0.329	1	CpDpCtD
Nabumetone—MPO—prostate cancer	0.228	0.727	CbGaD
Nabumetone—PTGS2—prostate cancer	0.0856	0.273	CbGaD
Nabumetone—CYP1A2—Flutamide—prostate cancer	0.0339	0.238	CbGbCtD
Nabumetone—CYP1A2—Estrone—prostate cancer	0.0245	0.172	CbGbCtD
Nabumetone—PTGS2—Etoposide—prostate cancer	0.0244	0.171	CbGbCtD
Nabumetone—PTGS1—Etoposide—prostate cancer	0.0206	0.144	CbGbCtD
Nabumetone—CYP1A2—Conjugated Estrogens—prostate cancer	0.016	0.112	CbGbCtD
Nabumetone—CYP1A2—Estradiol—prostate cancer	0.0141	0.0987	CbGbCtD
Nabumetone—CYP1A2—Etoposide—prostate cancer	0.00919	0.0644	CbGbCtD
Nabumetone—CYP1A2—urine—prostate cancer	0.00144	0.176	CbGeAlD
Nabumetone—Melatonin—CALR—prostate cancer	0.00121	0.395	CrCbGaD
Nabumetone—MPO—epithelium—prostate cancer	0.000696	0.0849	CbGeAlD
Nabumetone—MPO—renal system—prostate cancer	0.000645	0.0787	CbGeAlD
Nabumetone—Naproxen—AKR1C3—prostate cancer	0.000592	0.193	CrCbGaD
Nabumetone—MPO—bone marrow—prostate cancer	0.000488	0.0595	CbGeAlD
Nabumetone—PTGS1—prostate gland—prostate cancer	0.000449	0.0548	CbGeAlD
Nabumetone—PTGS2—prostate gland—prostate cancer	0.000429	0.0524	CbGeAlD
Nabumetone—MPO—testis—prostate cancer	0.000417	0.0509	CbGeAlD
Nabumetone—PTGS1—seminal vesicle—prostate cancer	0.00038	0.0463	CbGeAlD
Nabumetone—PTGS2—seminal vesicle—prostate cancer	0.000363	0.0443	CbGeAlD
Nabumetone—CYP1A2—renal system—prostate cancer	0.000353	0.0431	CbGeAlD
Nabumetone—PTGS1—epithelium—prostate cancer	0.00033	0.0403	CbGeAlD
Nabumetone—PTGS2—epithelium—prostate cancer	0.000316	0.0385	CbGeAlD
Nabumetone—PTGS1—renal system—prostate cancer	0.000306	0.0373	CbGeAlD
Nabumetone—MPO—lymph node—prostate cancer	0.000302	0.0369	CbGeAlD
Nabumetone—PTGS2—renal system—prostate cancer	0.000293	0.0357	CbGeAlD
Nabumetone—PTGS2—urethra—prostate cancer	0.000288	0.0351	CbGeAlD
Nabumetone—Melatonin—CYP1B1—prostate cancer	0.000265	0.0862	CrCbGaD
Nabumetone—Melatonin—MPO—prostate cancer	0.000238	0.0776	CrCbGaD
Nabumetone—PTGS2—bone marrow—prostate cancer	0.000221	0.027	CbGeAlD
Nabumetone—PTGS1—testis—prostate cancer	0.000198	0.0241	CbGeAlD
Nabumetone—Melatonin—CYP19A1—prostate cancer	0.000194	0.0632	CrCbGaD
Nabumetone—Melatonin—ESR1—prostate cancer	0.000179	0.0582	CrCbGaD
Nabumetone—PTGS1—lymph node—prostate cancer	0.000143	0.0175	CbGeAlD
Nabumetone—Melatonin—CYP2C19—prostate cancer	0.000143	0.0467	CrCbGaD
Nabumetone—Melatonin—CYP1A1—prostate cancer	0.000143	0.0465	CrCbGaD
Nabumetone—PTGS2—lymph node—prostate cancer	0.000137	0.0167	CbGeAlD
Nabumetone—Naproxen—PTGS2—prostate cancer	0.000104	0.0338	CrCbGaD
Nabumetone—Constipation—Etoposide—prostate cancer	4.57e-05	0.000346	CcSEcCtD
Nabumetone—Dizziness—Estradiol—prostate cancer	4.56e-05	0.000345	CcSEcCtD
Nabumetone—Dysuria—Doxorubicin—prostate cancer	4.56e-05	0.000345	CcSEcCtD
Nabumetone—Hypertension—Capecitabine—prostate cancer	4.55e-05	0.000345	CcSEcCtD
Nabumetone—Dry mouth—Docetaxel—prostate cancer	4.53e-05	0.000343	CcSEcCtD
Nabumetone—Haematuria—Epirubicin—prostate cancer	4.48e-05	0.000339	CcSEcCtD
Nabumetone—Confusional state—Docetaxel—prostate cancer	4.48e-05	0.000339	CcSEcCtD
Nabumetone—Anxiety—Capecitabine—prostate cancer	4.47e-05	0.000339	CcSEcCtD
Nabumetone—Photosensitivity reaction—Doxorubicin—prostate cancer	4.45e-05	0.000337	CcSEcCtD
Nabumetone—Oedema—Docetaxel—prostate cancer	4.44e-05	0.000336	CcSEcCtD
Nabumetone—Anaphylactic shock—Docetaxel—prostate cancer	4.44e-05	0.000336	CcSEcCtD
Nabumetone—Weight increased—Doxorubicin—prostate cancer	4.43e-05	0.000336	CcSEcCtD
Nabumetone—Discomfort—Capecitabine—prostate cancer	4.43e-05	0.000336	CcSEcCtD
Nabumetone—Weight decreased—Doxorubicin—prostate cancer	4.41e-05	0.000334	CcSEcCtD
Nabumetone—Feeling abnormal—Etoposide—prostate cancer	4.4e-05	0.000334	CcSEcCtD
Nabumetone—Hyperglycaemia—Doxorubicin—prostate cancer	4.39e-05	0.000333	CcSEcCtD
Nabumetone—Diarrhoea—Mitoxantrone—prostate cancer	4.39e-05	0.000333	CcSEcCtD
Nabumetone—Dry mouth—Capecitabine—prostate cancer	4.38e-05	0.000332	CcSEcCtD
Nabumetone—Vomiting—Estradiol—prostate cancer	4.38e-05	0.000332	CcSEcCtD
Nabumetone—Agranulocytosis—Epirubicin—prostate cancer	4.38e-05	0.000332	CcSEcCtD
Nabumetone—Pneumonia—Doxorubicin—prostate cancer	4.37e-05	0.000331	CcSEcCtD
Nabumetone—Gastrointestinal pain—Etoposide—prostate cancer	4.37e-05	0.000331	CcSEcCtD
Nabumetone—Shock—Docetaxel—prostate cancer	4.37e-05	0.000331	CcSEcCtD
Nabumetone—Ill-defined disorder—Prednisone—prostate cancer	4.35e-05	0.00033	CcSEcCtD
Nabumetone—Thrombocytopenia—Docetaxel—prostate cancer	4.35e-05	0.000329	CcSEcCtD
Nabumetone—Rash—Estradiol—prostate cancer	4.35e-05	0.000329	CcSEcCtD
Nabumetone—Dermatitis—Estradiol—prostate cancer	4.34e-05	0.000329	CcSEcCtD
Nabumetone—Anaemia—Prednisone—prostate cancer	4.34e-05	0.000329	CcSEcCtD
Nabumetone—Confusional state—Capecitabine—prostate cancer	4.33e-05	0.000328	CcSEcCtD
Nabumetone—Headache—Estradiol—prostate cancer	4.32e-05	0.000327	CcSEcCtD
Nabumetone—Agitation—Prednisone—prostate cancer	4.31e-05	0.000327	CcSEcCtD
Nabumetone—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	4.31e-05	0.000326	CcSEcCtD
Nabumetone—Oedema—Capecitabine—prostate cancer	4.3e-05	0.000326	CcSEcCtD
Nabumetone—Angioedema—Prednisone—prostate cancer	4.29e-05	0.000325	CcSEcCtD
Nabumetone—Renal failure—Doxorubicin—prostate cancer	4.27e-05	0.000324	CcSEcCtD
Nabumetone—Urticaria—Etoposide—prostate cancer	4.24e-05	0.000322	CcSEcCtD
Nabumetone—Haemoglobin—Epirubicin—prostate cancer	4.24e-05	0.000321	CcSEcCtD
Nabumetone—Jaundice—Doxorubicin—prostate cancer	4.23e-05	0.000321	CcSEcCtD
Nabumetone—Stomatitis—Doxorubicin—prostate cancer	4.23e-05	0.000321	CcSEcCtD
Nabumetone—Anorexia—Docetaxel—prostate cancer	4.23e-05	0.000321	CcSEcCtD
Nabumetone—Malaise—Prednisone—prostate cancer	4.23e-05	0.000321	CcSEcCtD
Nabumetone—Shock—Capecitabine—prostate cancer	4.23e-05	0.000321	CcSEcCtD
Nabumetone—Body temperature increased—Etoposide—prostate cancer	4.22e-05	0.00032	CcSEcCtD
Nabumetone—Abdominal pain—Etoposide—prostate cancer	4.22e-05	0.00032	CcSEcCtD
Nabumetone—Vertigo—Prednisone—prostate cancer	4.21e-05	0.000319	CcSEcCtD
Nabumetone—Haemorrhage—Epirubicin—prostate cancer	4.21e-05	0.000319	CcSEcCtD
Nabumetone—Thrombocytopenia—Capecitabine—prostate cancer	4.21e-05	0.000319	CcSEcCtD
Nabumetone—Syncope—Prednisone—prostate cancer	4.21e-05	0.000319	CcSEcCtD
Nabumetone—Hyperhidrosis—Capecitabine—prostate cancer	4.16e-05	0.000315	CcSEcCtD
Nabumetone—Haematuria—Doxorubicin—prostate cancer	4.14e-05	0.000314	CcSEcCtD
Nabumetone—Loss of consciousness—Prednisone—prostate cancer	4.12e-05	0.000313	CcSEcCtD
Nabumetone—Anorexia—Capecitabine—prostate cancer	4.1e-05	0.000311	CcSEcCtD
Nabumetone—Nausea—Estradiol—prostate cancer	4.09e-05	0.00031	CcSEcCtD
Nabumetone—Vomiting—Mitoxantrone—prostate cancer	4.08e-05	0.000309	CcSEcCtD
Nabumetone—Visual impairment—Epirubicin—prostate cancer	4.06e-05	0.000308	CcSEcCtD
Nabumetone—Agranulocytosis—Doxorubicin—prostate cancer	4.05e-05	0.000307	CcSEcCtD
Nabumetone—Hypertension—Prednisone—prostate cancer	4.05e-05	0.000307	CcSEcCtD
Nabumetone—Rash—Mitoxantrone—prostate cancer	4.05e-05	0.000307	CcSEcCtD
Nabumetone—Dermatitis—Mitoxantrone—prostate cancer	4.05e-05	0.000307	CcSEcCtD
Nabumetone—Headache—Mitoxantrone—prostate cancer	4.02e-05	0.000305	CcSEcCtD
Nabumetone—Insomnia—Docetaxel—prostate cancer	4.02e-05	0.000304	CcSEcCtD
Nabumetone—Paraesthesia—Docetaxel—prostate cancer	3.99e-05	0.000302	CcSEcCtD
Nabumetone—Erythema multiforme—Epirubicin—prostate cancer	3.99e-05	0.000302	CcSEcCtD
Nabumetone—Anxiety—Prednisone—prostate cancer	3.98e-05	0.000302	CcSEcCtD
Nabumetone—Dyspnoea—Docetaxel—prostate cancer	3.96e-05	0.0003	CcSEcCtD
Nabumetone—Somnolence—Docetaxel—prostate cancer	3.95e-05	0.000299	CcSEcCtD
Nabumetone—Discomfort—Prednisone—prostate cancer	3.95e-05	0.000299	CcSEcCtD
Nabumetone—Hypersensitivity—Etoposide—prostate cancer	3.94e-05	0.000298	CcSEcCtD
Nabumetone—Tinnitus—Epirubicin—prostate cancer	3.93e-05	0.000298	CcSEcCtD
Nabumetone—Haemoglobin—Doxorubicin—prostate cancer	3.92e-05	0.000297	CcSEcCtD
Nabumetone—Dyspepsia—Docetaxel—prostate cancer	3.91e-05	0.000296	CcSEcCtD
Nabumetone—Haemorrhage—Doxorubicin—prostate cancer	3.9e-05	0.000296	CcSEcCtD
Nabumetone—Insomnia—Capecitabine—prostate cancer	3.89e-05	0.000295	CcSEcCtD
Nabumetone—Paraesthesia—Capecitabine—prostate cancer	3.86e-05	0.000293	CcSEcCtD
Nabumetone—Decreased appetite—Docetaxel—prostate cancer	3.86e-05	0.000293	CcSEcCtD
Nabumetone—Asthenia—Etoposide—prostate cancer	3.83e-05	0.00029	CcSEcCtD
Nabumetone—Dyspnoea—Capecitabine—prostate cancer	3.83e-05	0.00029	CcSEcCtD
Nabumetone—Anaphylactic shock—Prednisone—prostate cancer	3.83e-05	0.00029	CcSEcCtD
Nabumetone—Oedema—Prednisone—prostate cancer	3.83e-05	0.00029	CcSEcCtD
Nabumetone—Fatigue—Docetaxel—prostate cancer	3.83e-05	0.00029	CcSEcCtD
Nabumetone—Nausea—Mitoxantrone—prostate cancer	3.81e-05	0.000289	CcSEcCtD
Nabumetone—Constipation—Docetaxel—prostate cancer	3.8e-05	0.000288	CcSEcCtD
Nabumetone—Dyspepsia—Capecitabine—prostate cancer	3.78e-05	0.000287	CcSEcCtD
Nabumetone—Chills—Epirubicin—prostate cancer	3.78e-05	0.000287	CcSEcCtD
Nabumetone—Pruritus—Etoposide—prostate cancer	3.78e-05	0.000286	CcSEcCtD
Nabumetone—Shock—Prednisone—prostate cancer	3.77e-05	0.000285	CcSEcCtD
Nabumetone—Arrhythmia—Epirubicin—prostate cancer	3.77e-05	0.000285	CcSEcCtD
Nabumetone—Visual impairment—Doxorubicin—prostate cancer	3.76e-05	0.000285	CcSEcCtD
Nabumetone—Decreased appetite—Capecitabine—prostate cancer	3.74e-05	0.000283	CcSEcCtD
Nabumetone—Alopecia—Epirubicin—prostate cancer	3.72e-05	0.000282	CcSEcCtD
Nabumetone—Fatigue—Capecitabine—prostate cancer	3.71e-05	0.000281	CcSEcCtD
Nabumetone—Hyperhidrosis—Prednisone—prostate cancer	3.7e-05	0.000281	CcSEcCtD
Nabumetone—Erythema multiforme—Doxorubicin—prostate cancer	3.69e-05	0.000279	CcSEcCtD
Nabumetone—Constipation—Capecitabine—prostate cancer	3.68e-05	0.000279	CcSEcCtD
Nabumetone—Feeling abnormal—Docetaxel—prostate cancer	3.66e-05	0.000277	CcSEcCtD
Nabumetone—Diarrhoea—Etoposide—prostate cancer	3.65e-05	0.000277	CcSEcCtD
Nabumetone—Anorexia—Prednisone—prostate cancer	3.65e-05	0.000277	CcSEcCtD
Nabumetone—Tinnitus—Doxorubicin—prostate cancer	3.64e-05	0.000276	CcSEcCtD
Nabumetone—Gastrointestinal pain—Docetaxel—prostate cancer	3.63e-05	0.000275	CcSEcCtD
Nabumetone—Flatulence—Epirubicin—prostate cancer	3.62e-05	0.000274	CcSEcCtD
Nabumetone—Tension—Epirubicin—prostate cancer	3.6e-05	0.000273	CcSEcCtD
Nabumetone—Nervousness—Epirubicin—prostate cancer	3.56e-05	0.00027	CcSEcCtD
Nabumetone—Feeling abnormal—Capecitabine—prostate cancer	3.54e-05	0.000268	CcSEcCtD
Nabumetone—Dizziness—Etoposide—prostate cancer	3.53e-05	0.000268	CcSEcCtD
Nabumetone—Gastrointestinal pain—Capecitabine—prostate cancer	3.51e-05	0.000266	CcSEcCtD
Nabumetone—Abdominal pain—Docetaxel—prostate cancer	3.51e-05	0.000266	CcSEcCtD
Nabumetone—Body temperature increased—Docetaxel—prostate cancer	3.51e-05	0.000266	CcSEcCtD
Nabumetone—Chills—Doxorubicin—prostate cancer	3.5e-05	0.000265	CcSEcCtD
Nabumetone—Arrhythmia—Doxorubicin—prostate cancer	3.48e-05	0.000264	CcSEcCtD
Nabumetone—Insomnia—Prednisone—prostate cancer	3.46e-05	0.000262	CcSEcCtD
Nabumetone—Alopecia—Doxorubicin—prostate cancer	3.45e-05	0.000261	CcSEcCtD
Nabumetone—Paraesthesia—Prednisone—prostate cancer	3.44e-05	0.000261	CcSEcCtD
Nabumetone—Urticaria—Capecitabine—prostate cancer	3.41e-05	0.000259	CcSEcCtD
Nabumetone—Ill-defined disorder—Epirubicin—prostate cancer	3.4e-05	0.000258	CcSEcCtD
Nabumetone—Body temperature increased—Capecitabine—prostate cancer	3.4e-05	0.000258	CcSEcCtD
Nabumetone—Abdominal pain—Capecitabine—prostate cancer	3.4e-05	0.000258	CcSEcCtD
Nabumetone—Vomiting—Etoposide—prostate cancer	3.4e-05	0.000257	CcSEcCtD
Nabumetone—Anaemia—Epirubicin—prostate cancer	3.39e-05	0.000257	CcSEcCtD
Nabumetone—Agitation—Epirubicin—prostate cancer	3.37e-05	0.000256	CcSEcCtD
Nabumetone—Dyspepsia—Prednisone—prostate cancer	3.37e-05	0.000255	CcSEcCtD
Nabumetone—Rash—Etoposide—prostate cancer	3.37e-05	0.000255	CcSEcCtD
Nabumetone—Dermatitis—Etoposide—prostate cancer	3.36e-05	0.000255	CcSEcCtD
Nabumetone—Headache—Etoposide—prostate cancer	3.35e-05	0.000254	CcSEcCtD
Nabumetone—Flatulence—Doxorubicin—prostate cancer	3.35e-05	0.000254	CcSEcCtD
Nabumetone—Tension—Doxorubicin—prostate cancer	3.33e-05	0.000252	CcSEcCtD
Nabumetone—Decreased appetite—Prednisone—prostate cancer	3.33e-05	0.000252	CcSEcCtD
Nabumetone—Malaise—Epirubicin—prostate cancer	3.31e-05	0.000251	CcSEcCtD
Nabumetone—Fatigue—Prednisone—prostate cancer	3.3e-05	0.00025	CcSEcCtD
Nabumetone—Nervousness—Doxorubicin—prostate cancer	3.3e-05	0.00025	CcSEcCtD
Nabumetone—Vertigo—Epirubicin—prostate cancer	3.3e-05	0.00025	CcSEcCtD
Nabumetone—Syncope—Epirubicin—prostate cancer	3.29e-05	0.000249	CcSEcCtD
Nabumetone—Leukopenia—Epirubicin—prostate cancer	3.28e-05	0.000249	CcSEcCtD
Nabumetone—Constipation—Prednisone—prostate cancer	3.27e-05	0.000248	CcSEcCtD
Nabumetone—Hypersensitivity—Docetaxel—prostate cancer	3.27e-05	0.000248	CcSEcCtD
Nabumetone—Palpitations—Epirubicin—prostate cancer	3.24e-05	0.000246	CcSEcCtD
Nabumetone—Loss of consciousness—Epirubicin—prostate cancer	3.22e-05	0.000244	CcSEcCtD
Nabumetone—Cough—Epirubicin—prostate cancer	3.2e-05	0.000243	CcSEcCtD
Nabumetone—Asthenia—Docetaxel—prostate cancer	3.19e-05	0.000241	CcSEcCtD
Nabumetone—Nausea—Etoposide—prostate cancer	3.17e-05	0.00024	CcSEcCtD
Nabumetone—Hypertension—Epirubicin—prostate cancer	3.17e-05	0.00024	CcSEcCtD
Nabumetone—Hypersensitivity—Capecitabine—prostate cancer	3.17e-05	0.00024	CcSEcCtD
Nabumetone—Feeling abnormal—Prednisone—prostate cancer	3.15e-05	0.000239	CcSEcCtD
Nabumetone—Ill-defined disorder—Doxorubicin—prostate cancer	3.15e-05	0.000239	CcSEcCtD
Nabumetone—Pruritus—Docetaxel—prostate cancer	3.14e-05	0.000238	CcSEcCtD
Nabumetone—Anaemia—Doxorubicin—prostate cancer	3.14e-05	0.000238	CcSEcCtD
Nabumetone—Gastrointestinal pain—Prednisone—prostate cancer	3.13e-05	0.000237	CcSEcCtD
Nabumetone—Agitation—Doxorubicin—prostate cancer	3.12e-05	0.000236	CcSEcCtD
Nabumetone—Anxiety—Epirubicin—prostate cancer	3.11e-05	0.000236	CcSEcCtD
Nabumetone—Discomfort—Epirubicin—prostate cancer	3.09e-05	0.000234	CcSEcCtD
Nabumetone—Asthenia—Capecitabine—prostate cancer	3.08e-05	0.000234	CcSEcCtD
Nabumetone—Malaise—Doxorubicin—prostate cancer	3.06e-05	0.000232	CcSEcCtD
Nabumetone—Dry mouth—Epirubicin—prostate cancer	3.05e-05	0.000232	CcSEcCtD
Nabumetone—Vertigo—Doxorubicin—prostate cancer	3.05e-05	0.000231	CcSEcCtD
Nabumetone—Syncope—Doxorubicin—prostate cancer	3.04e-05	0.000231	CcSEcCtD
Nabumetone—Urticaria—Prednisone—prostate cancer	3.04e-05	0.000231	CcSEcCtD
Nabumetone—Pruritus—Capecitabine—prostate cancer	3.04e-05	0.00023	CcSEcCtD
Nabumetone—Leukopenia—Doxorubicin—prostate cancer	3.04e-05	0.00023	CcSEcCtD
Nabumetone—Diarrhoea—Docetaxel—prostate cancer	3.04e-05	0.00023	CcSEcCtD
Nabumetone—Abdominal pain—Prednisone—prostate cancer	3.03e-05	0.000229	CcSEcCtD
Nabumetone—Body temperature increased—Prednisone—prostate cancer	3.03e-05	0.000229	CcSEcCtD
Nabumetone—Confusional state—Epirubicin—prostate cancer	3.02e-05	0.000229	CcSEcCtD
Nabumetone—Palpitations—Doxorubicin—prostate cancer	3e-05	0.000227	CcSEcCtD
Nabumetone—Anaphylactic shock—Epirubicin—prostate cancer	2.99e-05	0.000227	CcSEcCtD
Nabumetone—Oedema—Epirubicin—prostate cancer	2.99e-05	0.000227	CcSEcCtD
Nabumetone—Loss of consciousness—Doxorubicin—prostate cancer	2.98e-05	0.000226	CcSEcCtD
Nabumetone—Cough—Doxorubicin—prostate cancer	2.96e-05	0.000225	CcSEcCtD
Nabumetone—Shock—Epirubicin—prostate cancer	2.95e-05	0.000223	CcSEcCtD
Nabumetone—Diarrhoea—Capecitabine—prostate cancer	2.94e-05	0.000223	CcSEcCtD
Nabumetone—Dizziness—Docetaxel—prostate cancer	2.94e-05	0.000223	CcSEcCtD
Nabumetone—Thrombocytopenia—Epirubicin—prostate cancer	2.93e-05	0.000222	CcSEcCtD
Nabumetone—Hypertension—Doxorubicin—prostate cancer	2.93e-05	0.000222	CcSEcCtD
Nabumetone—Hyperhidrosis—Epirubicin—prostate cancer	2.89e-05	0.000219	CcSEcCtD
Nabumetone—Anxiety—Doxorubicin—prostate cancer	2.88e-05	0.000218	CcSEcCtD
Nabumetone—Discomfort—Doxorubicin—prostate cancer	2.86e-05	0.000216	CcSEcCtD
Nabumetone—Anorexia—Epirubicin—prostate cancer	2.85e-05	0.000216	CcSEcCtD
Nabumetone—Dizziness—Capecitabine—prostate cancer	2.84e-05	0.000215	CcSEcCtD
Nabumetone—Dry mouth—Doxorubicin—prostate cancer	2.83e-05	0.000214	CcSEcCtD
Nabumetone—Vomiting—Docetaxel—prostate cancer	2.82e-05	0.000214	CcSEcCtD
Nabumetone—Hypersensitivity—Prednisone—prostate cancer	2.82e-05	0.000214	CcSEcCtD
Nabumetone—Rash—Docetaxel—prostate cancer	2.8e-05	0.000212	CcSEcCtD
Nabumetone—Dermatitis—Docetaxel—prostate cancer	2.8e-05	0.000212	CcSEcCtD
Nabumetone—Confusional state—Doxorubicin—prostate cancer	2.79e-05	0.000212	CcSEcCtD
Nabumetone—Headache—Docetaxel—prostate cancer	2.78e-05	0.000211	CcSEcCtD
Nabumetone—Anaphylactic shock—Doxorubicin—prostate cancer	2.77e-05	0.00021	CcSEcCtD
Nabumetone—Oedema—Doxorubicin—prostate cancer	2.77e-05	0.00021	CcSEcCtD
Nabumetone—Asthenia—Prednisone—prostate cancer	2.75e-05	0.000208	CcSEcCtD
Nabumetone—Vomiting—Capecitabine—prostate cancer	2.73e-05	0.000207	CcSEcCtD
Nabumetone—Shock—Doxorubicin—prostate cancer	2.73e-05	0.000207	CcSEcCtD
Nabumetone—Thrombocytopenia—Doxorubicin—prostate cancer	2.71e-05	0.000206	CcSEcCtD
Nabumetone—Rash—Capecitabine—prostate cancer	2.71e-05	0.000205	CcSEcCtD
Nabumetone—Pruritus—Prednisone—prostate cancer	2.71e-05	0.000205	CcSEcCtD
Nabumetone—Insomnia—Epirubicin—prostate cancer	2.71e-05	0.000205	CcSEcCtD
Nabumetone—Dermatitis—Capecitabine—prostate cancer	2.71e-05	0.000205	CcSEcCtD
Nabumetone—Headache—Capecitabine—prostate cancer	2.69e-05	0.000204	CcSEcCtD
Nabumetone—Paraesthesia—Epirubicin—prostate cancer	2.69e-05	0.000204	CcSEcCtD
Nabumetone—Hyperhidrosis—Doxorubicin—prostate cancer	2.68e-05	0.000203	CcSEcCtD
Nabumetone—Dyspnoea—Epirubicin—prostate cancer	2.67e-05	0.000202	CcSEcCtD
Nabumetone—Somnolence—Epirubicin—prostate cancer	2.66e-05	0.000202	CcSEcCtD
Nabumetone—Anorexia—Doxorubicin—prostate cancer	2.64e-05	0.0002	CcSEcCtD
Nabumetone—Nausea—Docetaxel—prostate cancer	2.64e-05	0.0002	CcSEcCtD
Nabumetone—Dyspepsia—Epirubicin—prostate cancer	2.64e-05	0.0002	CcSEcCtD
Nabumetone—Diarrhoea—Prednisone—prostate cancer	2.62e-05	0.000199	CcSEcCtD
Nabumetone—Decreased appetite—Epirubicin—prostate cancer	2.6e-05	0.000197	CcSEcCtD
Nabumetone—Fatigue—Epirubicin—prostate cancer	2.58e-05	0.000196	CcSEcCtD
Nabumetone—Constipation—Epirubicin—prostate cancer	2.56e-05	0.000194	CcSEcCtD
Nabumetone—Nausea—Capecitabine—prostate cancer	2.55e-05	0.000194	CcSEcCtD
Nabumetone—Dizziness—Prednisone—prostate cancer	2.53e-05	0.000192	CcSEcCtD
Nabumetone—Insomnia—Doxorubicin—prostate cancer	2.51e-05	0.00019	CcSEcCtD
Nabumetone—Paraesthesia—Doxorubicin—prostate cancer	2.49e-05	0.000189	CcSEcCtD
Nabumetone—Dyspnoea—Doxorubicin—prostate cancer	2.47e-05	0.000187	CcSEcCtD
Nabumetone—Feeling abnormal—Epirubicin—prostate cancer	2.47e-05	0.000187	CcSEcCtD
Nabumetone—Somnolence—Doxorubicin—prostate cancer	2.46e-05	0.000187	CcSEcCtD
Nabumetone—Gastrointestinal pain—Epirubicin—prostate cancer	2.45e-05	0.000186	CcSEcCtD
Nabumetone—Dyspepsia—Doxorubicin—prostate cancer	2.44e-05	0.000185	CcSEcCtD
Nabumetone—Vomiting—Prednisone—prostate cancer	2.43e-05	0.000185	CcSEcCtD
Nabumetone—Rash—Prednisone—prostate cancer	2.41e-05	0.000183	CcSEcCtD
Nabumetone—Dermatitis—Prednisone—prostate cancer	2.41e-05	0.000183	CcSEcCtD
Nabumetone—Decreased appetite—Doxorubicin—prostate cancer	2.41e-05	0.000183	CcSEcCtD
Nabumetone—Headache—Prednisone—prostate cancer	2.4e-05	0.000182	CcSEcCtD
Nabumetone—Fatigue—Doxorubicin—prostate cancer	2.39e-05	0.000181	CcSEcCtD
Nabumetone—Urticaria—Epirubicin—prostate cancer	2.38e-05	0.00018	CcSEcCtD
Nabumetone—Constipation—Doxorubicin—prostate cancer	2.37e-05	0.00018	CcSEcCtD
Nabumetone—Abdominal pain—Epirubicin—prostate cancer	2.37e-05	0.000179	CcSEcCtD
Nabumetone—Body temperature increased—Epirubicin—prostate cancer	2.37e-05	0.000179	CcSEcCtD
Nabumetone—Feeling abnormal—Doxorubicin—prostate cancer	2.28e-05	0.000173	CcSEcCtD
Nabumetone—Nausea—Prednisone—prostate cancer	2.27e-05	0.000172	CcSEcCtD
Nabumetone—Gastrointestinal pain—Doxorubicin—prostate cancer	2.27e-05	0.000172	CcSEcCtD
Nabumetone—Hypersensitivity—Epirubicin—prostate cancer	2.21e-05	0.000167	CcSEcCtD
Nabumetone—Urticaria—Doxorubicin—prostate cancer	2.2e-05	0.000167	CcSEcCtD
Nabumetone—Abdominal pain—Doxorubicin—prostate cancer	2.19e-05	0.000166	CcSEcCtD
Nabumetone—Body temperature increased—Doxorubicin—prostate cancer	2.19e-05	0.000166	CcSEcCtD
Nabumetone—Asthenia—Epirubicin—prostate cancer	2.15e-05	0.000163	CcSEcCtD
Nabumetone—Pruritus—Epirubicin—prostate cancer	2.12e-05	0.000161	CcSEcCtD
Nabumetone—Diarrhoea—Epirubicin—prostate cancer	2.05e-05	0.000155	CcSEcCtD
Nabumetone—Hypersensitivity—Doxorubicin—prostate cancer	2.04e-05	0.000155	CcSEcCtD
Nabumetone—Asthenia—Doxorubicin—prostate cancer	1.99e-05	0.000151	CcSEcCtD
Nabumetone—Dizziness—Epirubicin—prostate cancer	1.98e-05	0.00015	CcSEcCtD
Nabumetone—Pruritus—Doxorubicin—prostate cancer	1.96e-05	0.000149	CcSEcCtD
Nabumetone—Vomiting—Epirubicin—prostate cancer	1.9e-05	0.000144	CcSEcCtD
Nabumetone—Diarrhoea—Doxorubicin—prostate cancer	1.9e-05	0.000144	CcSEcCtD
Nabumetone—Rash—Epirubicin—prostate cancer	1.89e-05	0.000143	CcSEcCtD
Nabumetone—Dermatitis—Epirubicin—prostate cancer	1.89e-05	0.000143	CcSEcCtD
Nabumetone—Headache—Epirubicin—prostate cancer	1.88e-05	0.000142	CcSEcCtD
Nabumetone—Dizziness—Doxorubicin—prostate cancer	1.83e-05	0.000139	CcSEcCtD
Nabumetone—Nausea—Epirubicin—prostate cancer	1.78e-05	0.000135	CcSEcCtD
Nabumetone—Vomiting—Doxorubicin—prostate cancer	1.76e-05	0.000134	CcSEcCtD
Nabumetone—Rash—Doxorubicin—prostate cancer	1.75e-05	0.000132	CcSEcCtD
Nabumetone—Dermatitis—Doxorubicin—prostate cancer	1.75e-05	0.000132	CcSEcCtD
Nabumetone—Headache—Doxorubicin—prostate cancer	1.74e-05	0.000132	CcSEcCtD
Nabumetone—Nausea—Doxorubicin—prostate cancer	1.65e-05	0.000125	CcSEcCtD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—CYP17A1—prostate cancer	8.59e-06	0.00012	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—CYP17A1—prostate cancer	8.51e-06	0.000119	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—prostate cancer	8.48e-06	0.000119	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—SLC22A1—prostate cancer	8.42e-06	0.000118	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	8.39e-06	0.000118	CbGpPWpGaD
Nabumetone—PTGS2—Disease—TGFBR1—prostate cancer	8.33e-06	0.000117	CbGpPWpGaD
Nabumetone—PTGS2—Disease—B2M—prostate cancer	8.33e-06	0.000117	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	8.32e-06	0.000117	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—SULT2A1—prostate cancer	8.21e-06	0.000115	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—prostate cancer	8.2e-06	0.000115	CbGpPWpGaD
Nabumetone—PTGS2—Disease—RPS19—prostate cancer	8.2e-06	0.000115	CbGpPWpGaD
Nabumetone—PTGS2—Disease—AKR1C3—prostate cancer	8.2e-06	0.000115	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—NCOA2—prostate cancer	8.18e-06	0.000115	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PRKACB—prostate cancer	8.15e-06	0.000114	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—NCOA2—prostate cancer	8.11e-06	0.000114	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—HPGD—prostate cancer	8.08e-06	0.000113	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—B4GALT4—prostate cancer	8.08e-06	0.000113	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—MED12—prostate cancer	8.07e-06	0.000113	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GNG5—prostate cancer	8.01e-06	0.000112	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PPP3CA—prostate cancer	7.95e-06	0.000111	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—SLC5A5—prostate cancer	7.74e-06	0.000109	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—NCOA3—prostate cancer	7.71e-06	0.000108	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PRKCZ—prostate cancer	7.69e-06	0.000108	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—TNFRSF21—prostate cancer	7.6e-06	0.000107	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	7.58e-06	0.000106	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—CYP2E1—prostate cancer	7.56e-06	0.000106	CbGpPWpGaD
Nabumetone—PTGS2—Disease—CALR—prostate cancer	7.55e-06	0.000106	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—NQO1—prostate cancer	7.47e-06	0.000105	CbGpPWpGaD
Nabumetone—PTGS2—Disease—FGFR4—prostate cancer	7.43e-06	0.000104	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PARP1—prostate cancer	7.43e-06	0.000104	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—MTAP—prostate cancer	7.39e-06	0.000104	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CYP7B1—prostate cancer	7.39e-06	0.000104	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—TH—prostate cancer	7.36e-06	0.000103	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—HPGDS—prostate cancer	7.36e-06	0.000103	CbGpPWpGaD
Nabumetone—PTGS2—Disease—CALCA—prostate cancer	7.33e-06	0.000103	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	7.32e-06	0.000103	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CYP2C19—prostate cancer	7.31e-06	0.000103	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—CYP3A4—prostate cancer	7.29e-06	0.000102	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	7.25e-06	0.000102	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—prostate cancer	7.23e-06	0.000101	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—SULT1E1—prostate cancer	7.21e-06	0.000101	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—SRD5A1—prostate cancer	7.21e-06	0.000101	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—CYP1B1—prostate cancer	7.16e-06	0.0001	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GSTT1—prostate cancer	7.14e-06	0.0001	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—ACHE—prostate cancer	7.14e-06	0.0001	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CYP2A6—prostate cancer	7.06e-06	9.9e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—HSPA1A—prostate cancer	7.03e-06	9.86e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	7.03e-06	9.86e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—prostate cancer	7e-06	9.82e-05	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—GGT1—prostate cancer	6.94e-06	9.73e-05	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	6.93e-06	9.72e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—NCOA1—prostate cancer	6.89e-06	9.67e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—ACSL4—prostate cancer	6.87e-06	9.64e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—HSD17B3—prostate cancer	6.87e-06	9.64e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—AKR1C3—prostate cancer	6.86e-06	9.63e-05	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—NCOA1—prostate cancer	6.83e-06	9.59e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PRKACB—prostate cancer	6.83e-06	9.58e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—prostate cancer	6.79e-06	9.53e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CYP17A1—prostate cancer	6.76e-06	9.48e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—CASP9—prostate cancer	6.75e-06	9.46e-05	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—CYP19A1—prostate cancer	6.74e-06	9.45e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	6.66e-06	9.35e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—UMPS—prostate cancer	6.59e-06	9.24e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PHGDH—prostate cancer	6.59e-06	9.24e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—ARG2—prostate cancer	6.59e-06	9.24e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—prostate cancer	6.56e-06	9.2e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PRKCQ—prostate cancer	6.54e-06	9.17e-05	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—RXRA—prostate cancer	6.5e-06	9.12e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—LDHB—prostate cancer	6.46e-06	9.07e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—NCOA2—prostate cancer	6.44e-06	9.03e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CYP3A5—prostate cancer	6.34e-06	8.9e-05	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	6.32e-06	8.87e-05	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—COMT—prostate cancer	6.26e-06	8.78e-05	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—GSTP1—prostate cancer	6.23e-06	8.74e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—FGF10—prostate cancer	6.21e-06	8.71e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—SLC5A5—prostate cancer	6.14e-06	8.62e-05	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—ITPR1—prostate cancer	6.13e-06	8.6e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—UCP3—prostate cancer	6.13e-06	8.59e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GSTA3—prostate cancer	6.13e-06	8.59e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PDHA1—prostate cancer	6.13e-06	8.59e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—TCN2—prostate cancer	6.13e-06	8.59e-05	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—EP300—prostate cancer	6.03e-06	8.46e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CYP2E1—prostate cancer	6e-06	8.42e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—NQO1—prostate cancer	5.93e-06	8.32e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—TGFBR2—prostate cancer	5.91e-06	8.29e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—TH—prostate cancer	5.85e-06	8.2e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—HSD3B1—prostate cancer	5.84e-06	8.2e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—SLC22A3—prostate cancer	5.84e-06	8.2e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—ITPR1—prostate cancer	5.81e-06	8.15e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	5.81e-06	8.15e-05	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—TYMS—prostate cancer	5.79e-06	8.13e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CYP3A4—prostate cancer	5.79e-06	8.12e-05	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—GSTM1—prostate cancer	5.73e-06	8.03e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CYP1B1—prostate cancer	5.69e-06	7.98e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—LPL—prostate cancer	5.67e-06	7.95e-05	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—LPL—prostate cancer	5.62e-06	7.89e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—TBXAS1—prostate cancer	5.6e-06	7.86e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GSTA4—prostate cancer	5.6e-06	7.86e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GGT1—prostate cancer	5.51e-06	7.73e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	5.48e-06	7.68e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GSTA2—prostate cancer	5.46e-06	7.66e-05	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—CYP1A1—prostate cancer	5.43e-06	7.62e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—NCOA1—prostate cancer	5.43e-06	7.61e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—SULT1A1—prostate cancer	5.39e-06	7.57e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—ABCG5—prostate cancer	5.39e-06	7.57e-05	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—ERCC2—prostate cancer	5.38e-06	7.55e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CYP19A1—prostate cancer	5.35e-06	7.5e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—LPL—prostate cancer	5.33e-06	7.48e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PDGFRB—prostate cancer	5.28e-06	7.41e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GSTA1—prostate cancer	5.27e-06	7.39e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—NAT2—prostate cancer	5.21e-06	7.31e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GSTO1—prostate cancer	5.21e-06	7.31e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—HSD3B2—prostate cancer	5.21e-06	7.31e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—RXRA—prostate cancer	5.16e-06	7.24e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—ERCC2—prostate cancer	5.1e-06	7.16e-05	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—MTHFR—prostate cancer	5.06e-06	7.1e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	5.02e-06	7.04e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	5.01e-06	7.03e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PLCB2—prostate cancer	4.99e-06	7.01e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CYP2C18—prostate cancer	4.99e-06	7.01e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—LRP2—prostate cancer	4.99e-06	7.01e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—ERBB3—prostate cancer	4.99e-06	7e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—FGFR2—prostate cancer	4.98e-06	6.99e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—COMT—prostate cancer	4.97e-06	6.97e-05	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PPARA—prostate cancer	4.97e-06	6.97e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GSTP1—prostate cancer	4.95e-06	6.94e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—P4HB—prostate cancer	4.9e-06	6.87e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—ITPR1—prostate cancer	4.87e-06	6.83e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—MTHFR—prostate cancer	4.8e-06	6.73e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	4.79e-06	6.71e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—TERT—prostate cancer	4.78e-06	6.71e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—SLC22A1—prostate cancer	4.76e-06	6.68e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	4.71e-06	6.61e-05	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—CAV1—prostate cancer	4.67e-06	6.55e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—SULT2A1—prostate cancer	4.64e-06	6.51e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—TYMS—prostate cancer	4.6e-06	6.45e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—HIF1A—prostate cancer	4.58e-06	6.42e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—MED12—prostate cancer	4.57e-06	6.41e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GSTM1—prostate cancer	4.55e-06	6.38e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GNG5—prostate cancer	4.53e-06	6.36e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—LPL—prostate cancer	4.46e-06	6.26e-05	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	4.46e-06	6.26e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—CAV1—prostate cancer	4.43e-06	6.21e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—NCOA3—prostate cancer	4.37e-06	6.12e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CYP1A1—prostate cancer	4.31e-06	6.05e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	4.29e-06	6.02e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—ERCC2—prostate cancer	4.27e-06	6e-05	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PIK3CG—prostate cancer	4.25e-06	5.97e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—HPGDS—prostate cancer	4.16e-06	5.84e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—BAD—prostate cancer	4.16e-06	5.84e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CYP2C19—prostate cancer	4.14e-06	5.81e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—ACHE—prostate cancer	4.04e-06	5.67e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GSTT1—prostate cancer	4.04e-06	5.67e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—APC—prostate cancer	4.03e-06	5.65e-05	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—INS—prostate cancer	4.03e-06	5.65e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—MTHFR—prostate cancer	4.02e-06	5.64e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CYP2A6—prostate cancer	3.99e-06	5.6e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—IRS1—prostate cancer	3.98e-06	5.59e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—EGF—prostate cancer	3.98e-06	5.59e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	3.98e-06	5.58e-05	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—CREBBP—prostate cancer	3.94e-06	5.53e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PPARA—prostate cancer	3.94e-06	5.53e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—AKR1C3—prostate cancer	3.88e-06	5.45e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—GSK3B—prostate cancer	3.87e-06	5.43e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PRKACB—prostate cancer	3.86e-06	5.42e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CYP17A1—prostate cancer	3.82e-06	5.36e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—INS—prostate cancer	3.82e-06	5.35e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	3.77e-06	5.29e-05	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PIK3CD—prostate cancer	3.74e-06	5.24e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—CREBBP—prostate cancer	3.74e-06	5.24e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CAV1—prostate cancer	3.71e-06	5.2e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—NCOA2—prostate cancer	3.64e-06	5.11e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—MAP2K1—prostate cancer	3.57e-06	5e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PIK3CD—prostate cancer	3.54e-06	4.97e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	3.54e-06	4.97e-05	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—NOS3—prostate cancer	3.53e-06	4.95e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—SERPINE1—prostate cancer	3.51e-06	4.92e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—SLC5A5—prostate cancer	3.48e-06	4.88e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CYP2E1—prostate cancer	3.4e-06	4.76e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—FGF2—prostate cancer	3.39e-06	4.76e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PIK3CG—prostate cancer	3.38e-06	4.74e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—NQO1—prostate cancer	3.36e-06	4.71e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—NOS3—prostate cancer	3.35e-06	4.69e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—TH—prostate cancer	3.31e-06	4.64e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	3.29e-06	4.61e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CYP3A4—prostate cancer	3.27e-06	4.59e-05	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PIK3CB—prostate cancer	3.26e-06	4.57e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	3.26e-06	4.57e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—JAK2—prostate cancer	3.25e-06	4.56e-05	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PTGS2—prostate cancer	3.23e-06	4.53e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CYP1B1—prostate cancer	3.22e-06	4.51e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—INS—prostate cancer	3.2e-06	4.48e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—MDM2—prostate cancer	3.17e-06	4.45e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CREBBP—prostate cancer	3.13e-06	4.39e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—ERBB2—prostate cancer	3.13e-06	4.39e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GGT1—prostate cancer	3.12e-06	4.37e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PIK3CB—prostate cancer	3.09e-06	4.33e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—NCOA1—prostate cancer	3.07e-06	4.31e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CYP19A1—prostate cancer	3.03e-06	4.24e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PIK3CD—prostate cancer	2.97e-06	4.16e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—RXRA—prostate cancer	2.92e-06	4.1e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—CDKN1B—prostate cancer	2.9e-06	4.07e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	2.84e-06	3.98e-05	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PTEN—prostate cancer	2.82e-06	3.95e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—COMT—prostate cancer	2.81e-06	3.95e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—NOS3—prostate cancer	2.8e-06	3.93e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GSTP1—prostate cancer	2.8e-06	3.93e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—ITPR1—prostate cancer	2.76e-06	3.86e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—CTNNB1—prostate cancer	2.74e-06	3.84e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	2.71e-06	3.8e-05	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—EP300—prostate cancer	2.69e-06	3.77e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—CDKN1A—prostate cancer	2.68e-06	3.75e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PTEN—prostate cancer	2.67e-06	3.74e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—TYMS—prostate cancer	2.6e-06	3.65e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PIK3CB—prostate cancer	2.59e-06	3.63e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GSTM1—prostate cancer	2.57e-06	3.61e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—EP300—prostate cancer	2.55e-06	3.57e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—LPL—prostate cancer	2.53e-06	3.54e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—SRC—prostate cancer	2.48e-06	3.47e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CYP1A1—prostate cancer	2.44e-06	3.42e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—ERCC2—prostate cancer	2.42e-06	3.39e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—STAT3—prostate cancer	2.39e-06	3.35e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—MTHFR—prostate cancer	2.27e-06	3.19e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PTEN—prostate cancer	2.24e-06	3.14e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PPARA—prostate cancer	2.23e-06	3.13e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—MYC—prostate cancer	2.22e-06	3.11e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—TGFB1—prostate cancer	2.21e-06	3.1e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—EGFR—prostate cancer	2.17e-06	3.04e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—EP300—prostate cancer	2.13e-06	2.99e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CAV1—prostate cancer	2.1e-06	2.94e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—KRAS—prostate cancer	2.05e-06	2.88e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2e-06	2.81e-05	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PIK3CA—prostate cancer	1.99e-06	2.79e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PIK3CG—prostate cancer	1.91e-06	2.68e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PIK3CA—prostate cancer	1.88e-06	2.64e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—INS—prostate cancer	1.81e-06	2.54e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CREBBP—prostate cancer	1.77e-06	2.48e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PIK3CD—prostate cancer	1.68e-06	2.36e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—IL6—prostate cancer	1.67e-06	2.34e-05	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—AKT1—prostate cancer	1.62e-06	2.28e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—NOS3—prostate cancer	1.59e-06	2.22e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PIK3CA—prostate cancer	1.58e-06	2.21e-05	CbGpPWpGaD
Nabumetone—PTGS2—Disease—AKT1—prostate cancer	1.54e-06	2.16e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PIK3CB—prostate cancer	1.46e-06	2.05e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PTGS2—prostate cancer	1.45e-06	2.03e-05	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—AKT1—prostate cancer	1.29e-06	1.81e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PTEN—prostate cancer	1.27e-06	1.77e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—EP300—prostate cancer	1.21e-06	1.69e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PIK3CA—prostate cancer	8.92e-07	1.25e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—AKT1—prostate cancer	7.29e-07	1.02e-05	CbGpPWpGaD
